Trials / Completed
CompletedNCT00047788
Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
A Phase Two Study of ZD6474 in Patients With Relapsed Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to assess the efficacy of ZD6474 when given orally to patients with relapsed multiple myeloma. A minimum of 15 and a maximum of 30 evaluable patients will be entered on study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD6474 | |
| DRUG | VEGF-receptor tyrosine kinase (KDR) |
Timeline
- Start date
- 2002-10-01
- Completion
- 2004-05-01
- First posted
- 2002-10-21
- Last updated
- 2016-08-24
Locations
7 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00047788. Inclusion in this directory is not an endorsement.